Roivant Sciences Ltd. ROIV
36.03 USD +0.14 (+0.39%)
Nov 3, 2026, 3:59 PM EST
35.56 Day range 36.78
19.32 52-week range 42.50
- YTD
- +66.04%
- 1 year
- +83.83%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 50.00 +38.8% upside
Now 36.03
- Target (low)
- 41.00
- Target (mean)
- 50.00
- Target (high)
- 62.00
Ratings (0m) 13 11 buy · 2 hold · 0 sell
- Strong buy2
- Buy9
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.44866 | -0.58598 – -0.35 | -0.2758 | -62.7% | 4.11M | +161.6% | 3 |
| Next quarter | -0.40348 | -0.50044 – -0.35 | -0.2397 | -68.3% | 14.39M | +619.7% | 3 |
| Current year | -1.56 | -1.89 – -1.23 | -1.08 | -44.4% | 57.27M | +593.3% | 3 |
| Next year | -1.39 | -1.93 – -0.59 | -1.56 | +10.6% | 428.65M | +648.5% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Citigroup | Maintained | Buy | Buy |
| Oct 12, 2026 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Sep 17, 2026 | Stifel | Initiated | — | Buy |
| Sep 9, 2026 | TD Cowen | Maintained | Buy | Buy |
| Sep 9, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 8, 2026 | Jefferies | Maintained | Buy | Buy |
| Aug 28, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 10, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 7, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 26, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 21, 2026 | Citigroup | Maintained | Buy | Buy |
| May 21, 2026 | TD Cowen | Maintained | Buy | Buy |
| May 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 16, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Mar 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 10, 2026 | Citigroup | Maintained | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 9, 2026 | Guggenheim | Maintained | Buy | Buy |
| Dec 15, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Dec 15, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 12, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 11, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 29, 2025 | Citigroup | Maintained | Buy | Buy |
| Sep 18, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Sep 18, 2025 | Jefferies | Maintained | Buy | Buy |
| Sep 18, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 18, 2025 | Guggenheim | Maintained | Buy | Buy |
| Sep 18, 2025 | Leerink Partners | Maintained | Outperform | Outperform |